TX45 Phase 1b data show 17.9% PCWP reduction in PH-HFpEF; >30% PVR cut in CpcPH subgroup

Tectonic Therapeutic, Inc.

TX45 achieved 17.9% reduction in PCWP (overall population) and >30% reduction in PVR in CpcPH patients.
Cardiac output increased 17.4%; mean pulmonary artery pressure reduced 15.9% across the total study.
No serious/severe adverse events, discontinuations, or significant hypotension; well tolerated.
APEX Phase 2 trial in PH-HFpEF is underway; topline results expected in 2026.
Data support enrichment of CpcPH patients in APEX; Part B of Phase 1b (PH-HFrEF) starts February 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.